Show simple item record

dc.contributor.authorTessier Cloutier, B
dc.contributor.authorClarke, A E
dc.contributor.authorRamsey-Goldman, R
dc.contributor.authorWang, Y
dc.contributor.authorFoulkes, W
dc.contributor.authorGordon, C
dc.contributor.authorHansen, J E
dc.contributor.authorYelin, E
dc.contributor.authorUrowitz, M B
dc.contributor.authorGladman, D
dc.contributor.authorFortin, P R
dc.contributor.authorWallace, D J
dc.contributor.authorPetri, M
dc.contributor.authorManzi, S
dc.contributor.authorGinzler, E M
dc.contributor.authorLabrecque, J
dc.contributor.authorEdworthy, S
dc.contributor.authorDooley, M A
dc.contributor.authorSenécal, J L
dc.contributor.authorPeschken, C A
dc.contributor.authorBae, S C
dc.contributor.authorIsenberg, D
dc.contributor.authorRahman, A
dc.contributor.authorRuiz-Irastorza, G
dc.contributor.authorHanly, J G
dc.contributor.authorJacobsen, S
dc.contributor.authorNived, O
dc.contributor.authorWitte, T
dc.contributor.authorCriswell, L A
dc.contributor.authorBarr, S G
dc.contributor.authorDreyer, L
dc.contributor.authorSturfelt, G
dc.contributor.authorBernatsky, S
dc.date.accessioned2023-02-06T20:35:38Z
dc.date.available2023-02-06T20:35:38Z
dc.date.issued2013-07-25
dc.identifier.citationTessier Cloutier B, Clarke AE, Ramsey-Goldman R, Wang Y, Foulkes W, Gordon C, Hansen JE, Yelin E, Urowitz MB, Gladman D, Fortin PR, Wallace DJ, Petri M, Manzi S, Ginzler EM, Labrecque J, Edworthy S, Dooley MA, Senécal JL, Peschken CA, Bae SC, Isenberg D, Rahman A, Ruiz-Irastorza G, Hanly JG, Jacobsen S, Nived O, Witte T, Criswell LA, Barr SG, Dreyer L, Sturfelt G, Bernatsky S. Breast cancer in systemic lupus erythematosus. Oncology. 2013;85(2):117-21. doi: 10.1159/000353138. Epub 2013 Jul 25. PMID: 23887245; PMCID: PMC3934367.en_US
dc.identifier.eissn1423-0232
dc.identifier.doi10.1159/000353138
dc.identifier.pmid23887245
dc.identifier.urihttp://hdl.handle.net/20.500.12648/8262
dc.description.abstractEvidence points to a decreased breast cancer risk in systemic lupus erythematosus (SLE). We analyzed data from a large multisite SLE cohort, linked to cancer registries.
dc.description.abstractInformation on age, SLE duration, cancer date, and histology was available. We analyzed information on histological type and performed multivariate logistic regression analyses of histological types according to age, SLE duration, and calendar year.
dc.description.abstractWe studied 180 breast cancers in the SLE cohort. Of the 155 cases with histology information, 11 were referred to simply as 'carcinoma not otherwise specified'. In the remaining 144 breast cancers, the most common histological type was ductal carcinoma (n = 95; 66%) followed by lobular adenocarcinoma (n = 11; 8%), 15 cancers were of mixed histology, and the remaining ones were special types. In our regression analyses, the independent risk factors for lobular versus ductal carcinoma was age [odds ratio (OR) 1.07, 95% confidence interval (CI) 1.01-1.14] and for the 'special' subtypes it was age (OR 1.06, 95% CI 1.01-1.10) and SLE duration (OR 1.05, 95% CI 1.00-1.11).
dc.description.abstractGenerally, up to 80% of breast cancers are ductal carcinomas. Though our results are not definitive, in the breast cancers that occur in SLE, there may be a slight decrease in the ductal histological type. In our analyses, age and SLE duration were independent predictors of histological status.
dc.language.isoenen_US
dc.relation.urlhttps://www.karger.com/Article/Abstract/353138en_US
dc.rightsCopyright © 2013 S. Karger AG, Basel.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleBreast cancer in systemic lupus erythematosus.en_US
dc.typeArticle/Reviewen_US
dc.source.journaltitleOncologyen_US
dc.source.volume85
dc.source.issue2
dc.source.beginpage117
dc.source.endpage21
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countrySwitzerland
dc.description.versionAMen_US
refterms.dateFOA2023-02-06T20:35:39Z
html.description.abstractEvidence points to a decreased breast cancer risk in systemic lupus erythematosus (SLE). We analyzed data from a large multisite SLE cohort, linked to cancer registries.
html.description.abstractInformation on age, SLE duration, cancer date, and histology was available. We analyzed information on histological type and performed multivariate logistic regression analyses of histological types according to age, SLE duration, and calendar year.
html.description.abstractWe studied 180 breast cancers in the SLE cohort. Of the 155 cases with histology information, 11 were referred to simply as 'carcinoma not otherwise specified'. In the remaining 144 breast cancers, the most common histological type was ductal carcinoma (n = 95; 66%) followed by lobular adenocarcinoma (n = 11; 8%), 15 cancers were of mixed histology, and the remaining ones were special types. In our regression analyses, the independent risk factors for lobular versus ductal carcinoma was age [odds ratio (OR) 1.07, 95% confidence interval (CI) 1.01-1.14] and for the 'special' subtypes it was age (OR 1.06, 95% CI 1.01-1.10) and SLE duration (OR 1.05, 95% CI 1.00-1.11).
html.description.abstractGenerally, up to 80% of breast cancers are ductal carcinomas. Though our results are not definitive, in the breast cancers that occur in SLE, there may be a slight decrease in the ductal histological type. In our analyses, age and SLE duration were independent predictors of histological status.
dc.description.institutionSUNY Downstateen_US
dc.description.departmentRheumatologyen_US
dc.description.degreelevelN/Aen_US
dc.identifier.journalOncology


Files in this item

Thumbnail
Name:
nihms554204.pdf
Size:
38.96Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Copyright © 2013 S. Karger AG, Basel.
Except where otherwise noted, this item's license is described as Copyright © 2013 S. Karger AG, Basel.